Details:
Cellvera holds worldwide rights (except Japan) to a broad spectrum oral antiviral drug targeting COVID-19 and other infectious diseases. Cellvera is focused on developing and commercializing antimicrobial therapies across a broad spectrum infectious diseases including Avigan.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Aditxt
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 05, 2022